av Øivind Enger | nov 7, 2019 | News
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients...
av Øivind Enger | nov 7, 2019 | News
In a communication during the Annual Meeting of the Society for Immunotherapy BerGen Bio announces that the company’s drug candidate Bemcentinib meets the primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda®. The primary efficacy...
av Øivind Enger | nov 4, 2019 | News
Sarsia Seed portfolio company WindSim AS enters into a strategic cooperation with leading wind power player Shanghai Electric. WindSim already have 100 customers in China now we have teamed up With #1 in offshore wind in the worlds largest and fastest growing market....
av Øivind Enger | aug 22, 2019 | News
Prophylix AS has just announced that the company in late June 2019 entered into a definitive agreement with Rallybio, a U.S.-based drug development company. Through the agreement Rallybio acquires two orphan drug programs from Prophylix AS, NAITgam and a follow-on...
av Sarsia | mai 23, 2019 | News
SonoClear publishes clinical data Bergen, May 23, 2019 In a newly published paper in Acta Neurologica the scientists behind the invention of the new acoustic coupling fluid (ACF) for intrasurgical application of ultrasound during neurosurgery publish very promising...
av Sarsia | mai 23, 2019 | News
BerGenBio to present new NSCLC and AMLclinical data and biomarker data from phase II development programme with selective AXL inhibitor Bemcentinib at ASCO2019 Bergen, May 23, 2019 BerGenBio notes the publication of abstracts relating to new interim clinical and...
